Plus therapeutics reports respect-gbm clinical trial update at the 2024 congress of neurological surgeons annual meeting

Rhenium ( 186 re) obisbemeda delivered by convection enhanced delivery (ced) continues to show safety, response, and potential efficacy mean phase 2 absorbed dose was 300 gy and 89% of patients exceeded the minimal dose threshold of 100 gy respect-gbm phase 1/2 trial has expanded to two new sites at leading u.s. academic medical centers in new york and upper midwest austin, texas, oct. 01, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers presented an update on the ongoing respect-gbm phase 1/2 clinical trial, evaluating the company's lead asset rhenium (186re) obisbemeda for the treatment of recurrent glioblastoma. the data were presented at the 2024 congress of neurological surgeons (cns) annual meeting on september 30, 2024, in houston, texas.
pstv Ratings Summary
pstv Quant Ranking